Ignyta Company
%20.jpg)
Ignyta is a scientifically driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goals are to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Investors
Connections from
Last Funding Type:
Post-IPO Equity
Funding Status:
M&A
Headquarters:
San Diego, California, United States
Founded Date:
2011-01-01
Investor Type:
For Profit
Total Funding:
$375.5M
Technology:
P4 Medicine
Employee Number:
101-250
Acquisitions Number:
1
Estimated Revenue:
Less than $1M
Investors Number:
5
Industry:
Biotechnology, Health Care, Health Diagnostics